杨良权,周东光,娄欢欢,毛大华
YANG Liangquan,ZHOU Dongguang,LOU Huanhuan,MAO Dahua

• 1:秦皇岛市妇幼保健院乳腺科
• 2:秦皇岛市开发区医院外科
• 3:贵州医科大学附院

摘要(Abstract)：

目的:分析DNA拓扑异构酶Ⅱα(TOPⅡα)在乳腺癌中的表达。方法:收集141例病理确诊的乳腺癌组织,采用免疫组织化学的方法检测癌组织中TOPⅡα的表达,分析TOPⅡα表达与乳腺癌患者年龄、家族史、月经状况、肿瘤大小、有无淋巴结转移及病理分级的关系,观察TOPⅡα在不同分子分型(Luminal A型、B样型、B-like型,HER2表达型及三阴性)乳腺癌中的表达。结果:TopⅡα表达水平与乳腺癌患者的年龄、家族史、月经状况、肿瘤大小及是否有淋巴结转移无关(P>0.05),与乳腺癌病理分级有关(P<0.05),随肿瘤组织学分级越高,TopⅡα表达水平越高;TopⅡα在Luminal B-like型、HER2表达型和三阴性乳腺癌患者中明显高表达,在Luminal A型和B样型中低表达。结论:TopⅡα表达水平与乳腺癌病理分级及分子分型有关。
Objective: To analyze expression and clinical significance of TOP II α in breast cancer.Methods: The breast cancer tissues were collected from 141 patients with pathologically diagnosed breast cancer. The expression of Top II α in cancer tissue was detected by immunohistochemistry. The correlation between the expression of Top II α and age of patients,family history,menstrual status,tumor size,lymph node metastasis and pathological grades were analyzed. The expression of Top II αin different molecular type of breast cancer( luminal A type,B type,B-like type,HER2 expression type and triple negative breast cancer) were observed. Results: There was no correlation between the expression level of Top II α and age of patients,family history,menstrual status,tumor size and lymph node metastasis( P > 0. 05). There existed a positive correlation between Top II α expression level and pathological grades of breast cancer( P < 0. 05). The higher pathological grade,the more Top II α expression. There was a significantly high expression of Top II α in the luminal B-like type,HER2 expression type and triple negative breast cancer while there was a significantly low expression in luminal A type and B type breast cancer. Conclusion: Top II α expression level is related to pathological grades and molecular type of breast cancer.

关键词(KeyWords)： 乳腺肿瘤;DNA拓扑异构酶Ⅱα;基因表达;免疫组织化学
breast cancer;topoisomerase II α;gene expression;immunohistochemistry

Abstract:

Keywords:

基金项目(Foundation): 河北省科技厅项目(152777118)

作者(Author): 杨良权,周东光,娄欢欢,毛大华
YANG Liangquan,ZHOU Dongguang,LOU Huanhuan,MAO Dahua

DOI: 10.19367/j.cnki.1000-2707.2016.06.025

参考文献(References)：

• [1]Park K,Kim J,Lim S,et al.Topoisomerase II-alpha(topo II)and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy[J].European Journal of Cancer,2003(5):631-634.
• [2]施为建,王渝芝,蒋凤莲,等.乳腺浸润性导管癌中多药耐药相关蛋白的表达情况[J].中国健康月刊,2011(8):15-16.
• [3]Andrea JE,Adachi K,Morgan AR.Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs:quantitation of catalytic activity and DNA cleavage[J].Molecular Pharmacology,1991(4):495-501.
• [4]钱晨彭,再利,巢晖.靶向抑制DNA拓扑异构酶的抗肿瘤药物研究[J].大学化学,2014(1):1-10.
• [5]潘亚奇,袁公,杨艳维.DNA拓扑异构酶Ⅱα与肿瘤[J].医学信息,2011(2):415.
• [6]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013版)[J].中国癌症杂志,2013(8):637-693.
• [7]Konecny GE,Untch M.HER2 gene amplification and response to dose dense sequential epirubicin and paclitaxel as neoadjuvant therapy of primary breast cancer[J].Breast Cancer Res Treat,2006(1):48.
• [8]Siddiqa A,Long LM,Li L,et al.Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase(ERK)and phosphoinositide-3 kinase(PI3K)signalling pathways[J].BMC Cancer,2008(8):129.
• [9]Di Leo A,Larsimont D,Gabcberg D,et al.HER-2 and topo-isomerase IIαas predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide[J].Ann Oncol,2001(8):1081-1089.
• [10]Mac Grogan G,Rudolph P,De Mascarel I.DNA topoisomerase II alpha expression and the response to primary chemotherapy in breast cancer[J].British Journal of Cancer,2003(5):666-671.
• [11]王云翔,范宇,张勤,等.TopⅡα蛋白在不同分子亚型乳腺癌中的表达及其预后价值[J].中国肿瘤临床,2012(7):129-130.
• [12]Tan DS,Marchio C,Jones RL.Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracycline-treated patients[J].Breast Cancer Research and Treatment,2008(1):27-44.
• [13]王晓文,杨亮,朱丽萍,等.Ki-67及TopⅡα在三阴乳腺癌中的表达及意义[J].中国普通外科杂志,2014(5):692-694.
• [14]况丽平,王媛媛,管慧红,等.TopⅡα和Ki-67在不同分子分型乳腺癌组织中的表达及意义[J].实用医学杂志,2014(5):778-780.
• [15]陈秋兰,周绍荣,焦兰农,等.乳腺癌组织中HER-2、VEGF和Ki67的表达及临床意义[J].实用临床医药杂志,2015(15):38-40.

文章评论(Comment)：